Literature DB >> 9731895

The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.

V Ahuja1, R E Coleman, J Herndon, E F Patz.   

Abstract

BACKGROUND: A fundamental property of malignant tumors is increased glucose metabolism, which can be estimated by imaging the glucose analog fluorodeoxyglucose (FDG). The aim of this study was to determine whether FDG uptake in lung carcinoma, as measured on positron emission tomography (PET) imaging in patients with newly diagnosed bronchogenic carcinoma, has prognostic significance.
METHODS: A retrospective review of all patients with a new diagnosis of nonsmall cell lung carcinoma and FDG-PET imaging was performed. Stage at presentation, cell type, tumor size, and survival data were recorded. For each patient, a standardized uptake ratio (SUR) was calculated for the primary lesion on PET and was correlated with clinical information to determine prognostic significance.
RESULTS: One hundred fifty-five patients, with a mean age of 56 years, were enrolled. One hundred eighteen patients (76%) had lesions with SUR values <10 and had a median survival of 24.6 months (95% confidence interval [CI]: 20.9-41.1). Thirty-seven patients (24%) had tumor lesions with SUR values >10 and had a median survival of 11.4 months (95% CI: 9.3-19.4). An SUR >10 correlated with poorer survival (P = 0.0049). Patients with primary lesions >3 cm and an SUR > 10 had the worst prognosis, with a median survival of 5.7 months (95% CI: 4.0-13.1). Multivariate analysis demonstrated than an SUR > 10 provided prognostic information independent of the clinical stage and lesion size.
CONCLUSIONS: On PET studies of patients with lung carcinoma, FDG uptake within the primary lesion correlates with survival.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731895

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  45 in total

1.  Is quantitation necessary for oncological PET studies? For.

Authors:  R Edward Coleman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2001-11-14       Impact factor: 9.236

2.  Requirements for clinical PET: comparisons within Europe.

Authors:  Michael Bedford; Michael N Maisey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

3.  The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.

Authors:  Alejandro G Levy; Peter E Zage; Lauren J Akers; Maurizio L Ghisoli; Zhao Chen; Wendy Fang; Sankaranarayanan Kannan; Timothy Graham; Lizhi Zeng; Anna R Franklin; Peng Huang; Patrick A Zweidler-McKay
Journal:  Invest New Drugs       Date:  2010-10-05       Impact factor: 3.850

4.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Authors:  Dirk Hellwig; Andreas Gröschel; Thomas P Graeter; Anne P Hellwig; Ursula Nestle; Hans-Joachim Schäfers; Gerhard W Sybrecht; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

5.  Initial clinical results for breath-hold CT-based processing of respiratory-gated PET acquisitions.

Authors:  Loïc Fin; Joël Daouk; Julie Morvan; Pascal Bailly; Isabelle El Esper; Lazhar Saidi; Marc-Etienne Meyer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-26       Impact factor: 9.236

6.  PET-CT in the staging and treatment of non-small-cell lung cancer.

Authors:  Patricia Ibeas; Blanca Cantos; José Manuel Gasent; Begoña Rodríguez; Mariano Provencio
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

Review 7.  Clinical oncologic applications of PET/MRI: a new horizon.

Authors:  Sasan Partovi; Andres Kohan; Christian Rubbert; Jose Luis Vercher-Conejero; Chiara Gaeta; Roger Yuh; Lisa Zipp; Karin A Herrmann; Mark R Robbin; Zhenghong Lee; Raymond F Muzic; Peter Faulhaber; Pablo R Ros
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

8.  Comparison of prognostic values of primary tumor and nodal 18F-fluorodeoxyglucose uptake in non-small cell lung cancer with N1 disease.

Authors:  Chae Hong Lim; Seung Hyup Hyun; Seung Hwan Moon; Young Seok Cho; Joon Young Choi; Kyung-Han Lee
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

Review 9.  Positron emission tomography/computerized tomography in lung cancer.

Authors:  Ilgin Sahiner; Gulin Ucmak Vural
Journal:  Quant Imaging Med Surg       Date:  2014-06

10.  Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer.

Authors:  I Brink; T Schumacher; M Mix; S Ruhland; E Stoelben; W Digel; M Henke; N Ghanem; E Moser; E U Nitzsche
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.